FDA Needs More Oversight Power To Protect Increasingly Globalized Drug Supply, Pew Report Says

“The Food and Drug Administration needs much more power to protect the U.S. supply of drugs as more and more are made in other countries,” according to a report released Tuesday by the Pew Health Group, National Journal reports. The FDA estimates about 80 percent of the active ingredients in medications and up to 40 percent of finished pharmaceuticals are manufactured abroad, often in developing countries with little to no regulatory oversight, the news service adds.

“FDA has increased inspections in the United States and abroad, and in June the agency announced a global strategy to ensure safety of imported products,” but “it doesn’t have the regulatory power to recall drugs, nor does it have a large presence in other countries where products are exported,” National Journal writes. “In addition to recommending stricter legislation and more international oversight, the Pew report also recommended pharmaceutical companies do more to regulate themselves,” according to the news service (Fung, 7/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.